For the year ending 2025-12-31, HNGE had -$92,790K decrease in cash & cash equivalents over the period. $170,733K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 587,860 |
| Excess and obsolete inventory charge | 0 |
| Restructuring, acquisition and other expenses | 5,351 |
| Stock-based compensation expense | 643,009 |
| Other segment expenses | -644 |
| Cost of revenue | 98,735 |
| Research and development | 89,709 |
| Sales and marketing | 207,890 |
| General and administrative | 72,071 |
| Net loss | -528,261 |
| Depreciation and amortization | 5,133 |
| Stock-based compensation | 643,009 |
| Amortization of deferred commissions | 46,667 |
| Accretion of discounts and amortization of premiums on marketable securities, net | -361 |
| Excess and obsolete inventory charge | 0 |
| Non-cash operating lease expense | 3,431 |
| Provision for credit losses | 3,061 |
| Deferred income taxes | 53 |
| Other | -1 |
| Accounts receivable | 26,627 |
| Deferred commissions | -63,579 |
| Inventory | 4,763 |
| Prepaid expenses and other current assets | 15,775 |
| Other assets | 181 |
| Accounts payable and accrued liabilities | 29,407 |
| Operating lease liabilities | -3,719 |
| Deferred revenue | 83,223 |
| Net cash provided by (used in) operating activities | 171,441 |
| Purchase of property and equipment | 708 |
| Capitalized internal use software | 5,356 |
| Purchases of marketable securities | 472,288 |
| Maturities of marketable securities | 368,589 |
| Acquisition of a business | 4,000 |
| Net cash (used in) provided by investing activities | -113,763 |
| Proceeds from exercise of common stock options | 1,416 |
| Issuance of common stock in connection with the employee stock purchase plan | 8,113 |
| Proceeds from issuance of common stock in initial public offering, net of issuance costs | 255,675 |
| Tax withholdings on settlement of restricted stock units and performance-based restricted stock units | 295,229 |
| Payment on repurchase agreement with coatue | 50,000 |
| Proceeds from repayment of non-recourse loans to employees | 4,934 |
| Repurchase and retirement of common stock | 65,028 |
| Cash paid on settlement of acquisition related holdback | 0 |
| Payments for deferred offering costs | 10,349 |
| Net cash used in financing activities | -150,468 |
| Net increase (decrease) in cash | -92,790 |
| Cash, cash equivalents and restricted cash, beginning of period | 302,586 |
| Cash, cash equivalents and restricted cash, end of period | 209,796 |
Hinge Health, Inc. (HNGE)
Hinge Health, Inc. (HNGE)